On October 29, 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal vaccine (Trumenba®). FDA approved this vaccine for use in people 10 through 25 years old as a 3-dose series. On January 23, 2015, FDA licensed a second serogroup B meningococcal vaccine (Bexsero®). FDA approved this vaccine for use in people 10 through 25 years old as a 2-dose series. Clinicians can use serogroup B meningococcal vaccines for people 10 through 25 years old consistent with the labeled indication.
Vaccines are now available that help protect against all three serogroups (B, C, and Y) of meningococcal disease that are commonly seen in the United States:
- Meningococcal conjugate vaccine (Menactra®, Menveo® and MenHibrix®)
- Meningococcal polysaccharide vaccine (Menomune®)
- Serogroup B meningococcal vaccine (Bexsero® and Trumenba®)
For more information on meningococcal vaccines and who should receive them, visit the Meningococcal Vaccine site or Recommendations of the Advisory Committee on Immunization Practices.
- Meningococcal Vaccine Basics
Offers comprehensive information about meningococcal vaccines and other educational tools.
- Who Should Get Vaccinated
- Who Should Not Get Vaccinated
- Possible Reactions to Vaccination
- Vaccine Safety
Meningococcal Vaccine Resources for Health Care Professionals
- Meningococcal Vaccination
- Interim Guidance for Control of Serogroup B Meningococcal Disease Outbreaks in Organizational Settings [6 pages]
- Provider Education
- Page last reviewed: June 11, 2015
- Page last updated: June 11, 2015
- Content source:
- Content source: National Center for Immunization and Respiratory Diseases